Pleiotrophin Levels in Lung Cancer Patients
Author Information
Author(s): R. Jäger, B. List, C. Knabbe, B. Souttou, D. Raulais, T. Zeiler, A. Wellstein, A. Aigner, A. Neubauer, G. Zugmaier
Primary Institution: Philipps University of Marburg
Hypothesis
Pleiotrophin serum levels may serve as an early indicator of lung cancer and correlate with disease stage.
Conclusion
Pleiotrophin serum levels are significantly elevated in lung cancer patients and may be useful for monitoring therapy efficacy.
Supporting Evidence
- Pleiotrophin serum levels were elevated in 81% of lung cancer patients compared to controls.
- The mean serum concentration of pleiotrophin was 10.8-fold higher in lung cancer patients than in healthy controls.
- Pleiotrophin levels correlated positively with disease stage and inversely with therapy response.
Takeaway
This study found that a substance called pleiotrophin is much higher in the blood of lung cancer patients than in healthy people, which could help doctors know how serious the cancer is.
Methodology
The study measured serum and plasma pleiotrophin levels in lung cancer patients and healthy controls using a specific ELISA test.
Limitations
The study had a small sample size for some patient groups, which may limit the generalizability of the findings.
Participant Demographics
63 patients with small cell lung cancer (SCLC) and 22 patients with non-small cell lung cancer (NSCLC), compared to 41 healthy controls.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website